Sun Pharma Q4 FY21 net profit up 124%
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Subscribe To Our Newsletter & Stay Updated